0
MediWound Ltd. Banner Image

MediWound Ltd. has reached its limit for free report views

Work for MediWound Ltd.? Upgrade Your Profile and unlock all your annual reports.

MediWound Ltd.

  • Ticker MDWD
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
MediWound Ltd. Logo Image
  • 51-200 Employees
  • Based in Yavne, Israel
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid®, non-surgically and rapidly removes burn escharMore without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWound’s second innovative product, EscharEx® is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
MediWound Ltd.

Most Recent Annual Report

MediWound Ltd. MOST RECENT 2019 Annual Report

Report Locked. MediWound Ltd. has reached its limit for free report views.

Older/Archived Annual Reports